What is the 13F Pro Quality Score for MGNX?

13F Pro ranks MACROGENICS INC (MGNX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MGNX's current score at https://13fpro.ai/research/MGNX (free sign-up required for the full ranking).

Where does 13F Pro source MGNX data?

All MACROGENICS INC fundamentals and ownership data come directly from SEC EDGAR. MACROGENICS INC files with the SEC under CIK 1125345. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MGNX in?

MACROGENICS INC (MGNX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MGNX research updated on 13F Pro?

MGNX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MACROGENICS INC(MGNX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1125345 MGNX stock profile & AI dashboard →

13F Pro Quality Score

31.7/100

Rank #2,302 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

92.2/100

Profitability

8.3/100

Balance Sheet

5.3/100

Earnings Quality

30.0/100

Free Cash Flow

6.2/100

Institutional Flow

91.2/100

Revenue Scale

20.0/100

Dilution Risk

17.3/100

MGNX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MACROGENICS INC (MGNX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MGNX at 31.7/100 on a 32-signal composite quality model, placing it at rank #2,302 of 2,879 stocks — the bottom half of the AI-ranked universe. MGNX scores in the top quartile across revenue growth (92.2), institutional flow (91.2). Areas of concern include balance sheet strength (5.3) and free cash flow (6.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MACROGENICS INC reports quarterly revenue of $20.8M, net income of $-36.8M, free cash flow of $-36.2M. Top institutional holders of MGNX by reported 13-F value include ARMISTICE CAPITAL,, RENAISSANCE TECHNOLOGIES, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. MGNX trades on the Nasdaq exchange and files with the SEC under CIK 1125345. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MGNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MACROGENICS INC directly from SEC EDGAR. MACROGENICS INC's 13F Pro composite quality score has ranged between 8 and 66 since 2021, currently 31.7 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about MACROGENICS INC

Quirks, history, and lore behind MGNX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Maryland · focused on immuno-oncology.
2
The Numbers
A small-cap biotech with revenue largely derived from collaboration agreements rather than approved product sales — the classic pre-commercial drug-developer math.
3
The History
Founded in the late 1990s, the company built its entire platform around a proprietary antibody engineering technology it calls Fc Optimization, designed to make cancer-fighting antibodies hit harder.
4
The Secret
Its secret weapon is the DART platform — Dual-Affinity Re-Targeting — molecules engineered to grab two targets at once and redirect immune cells to destroy tumors.
5
The Lore
The company has inked partnerships with Zymeworks, Incyte, and Janssen, betting that its bispecific antibody approach will crack cancers that single-target drugs keep missing.
6
The Giveaway
Ticker MGNX, a Rockville, MD biotech whose name literally fuses "macro" with "genetics" — and whose DART-based pipeline is aimed squarely at blood cancers and solid tumors.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$20.8M

Net Income

Q1 2026

$-36.8M

Free Cash Flow

Q1 2026

$-36.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+96.2% YoY

$151.9MFY 2022

FY16 $91.9MFY19 $64.2MFY21 $77.4MFY22 $151.9M

Net Income

+40.7% YoY

$-119.8MFY 2022

FY16 $-58.5MFY19 $-151.8MFY21 $-202.1MFY22 $-119.8M

Operating Income

+40.1% YoY

$-121.4MFY 2022

FY16 $-60.0MFY19 $-177.2MFY21 $-202.8MFY22 $-121.4M

EPS (Diluted)

+42.1% YoY

$-1.95FY 2022

FY16 —FY19 —FY21 $-3.37FY22 $-1.95

Total Assets

-16.3% YoY

$280.5MFY 2022

FY16 $311.3MFY19 $312.5MFY21 $335.2MFY22 $280.5M

Op. Cash Flow

+39.5% YoY

$-87.0MFY 2022

FY16 —FY19 $-134.3MFY21 $-143.8MFY22 $-87.0M

Metric	FY 2022	FY 2021	FY 2019	FY 2016	FY 2015	FY 2013
Revenue	$151.9M +96.2%	$77.4M +20.7%	$64.2M -30.1%	$91.9M -8.9%	$100.9M +73.8%	$58.0M
Net Income	$-119.8M +40.7%	$-202.1M -33.1%	$-151.8M -159.4%	$-58.5M -190.6%	$-20.1M -7616.5%	$-261.0K
Operating Income	$-121.4M +40.1%	$-202.8M -14.5%	$-177.2M -195.1%	$-60.0M -197.5%	$-20.2M -5614.2%	$366.0K
EPS (Diluted)	$-1.95 +42.1%	$-3.37	—	—	—	$-0.04
Total Assets	$280.5M -16.3%	$335.2M +7.3%	$312.5M +0.4%	$311.3M -13.4%	$359.3M +185.6%	$125.8M
Operating Cash Flow	$-87.0M +39.5%	$-143.8M -7.1%	$-134.3M	—	—	$-14.2M

AI Insight: MGNX Financial Trends

MGNX swung from Q3 2025 profitability back to losses across all metrics in Q1 2026, with equity halving to $21M.

• Revenue collapsed 49% from Q3 2025 ($73M) to Q1 2026 ($21M), erasing prior quarter gains.

• Net income returned to $-37M loss in Q1 2026 after isolated $17M profit in Q3 2025.

• Equity declined 69% from Q3 2025 ($67M) to Q1 2026 ($21M), signaling rapid cash burn.

⚠ Operating cash flow turned positive $43M in Q4 2025 but reverted to $-36M burn in Q1 2026—volatility signals execution risk.

⚠ Q3 2025 was only profitable quarter in 8-quarter window; sustainability unclear given Q1 2026 relapse.

AI Insight: MGNX Ratio Trends

MGNX swung from Q3 2025 profitability (25.6% OpMargin, 24.9% ROA) to severe losses in Q4 2025 and Q1 2026, signaling operational distress.

• Operating margin collapsed to -161.0% in Q1 2026 from +25.6% in Q3 2025; NPM deteriorated to -177.0% from +23.1%.

• ROA declined from +24.9% (Q3 2025) to -67.5% (Q1 2026), indicating severe asset-base value destruction.

• TTM metrics show -40.5% OpMargin, -44.8% NPM, and -32.3% ROA—all deeply negative.

⚠ Q3 2025 profitability reversal in Q4–Q1 suggests one-time charge, impairment, or genuine operational breakdown. Root cause critical.

⚠ ROIC data sparse; only Q4 2025 available at -87.0%, consistent with capital destruction narrative.

Get alerted when MGNX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MACROGENICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MGNX

ARMISTICE CAPITAL, LLC
$17.4M6,012,000 sh
RENAISSANCE TECHNOLOGIES LLC
$8.6M2,963,559 sh
MILLENNIUM MANAGEMENT LLC
$8.1M2,794,357 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.7M2,653,853 sh
TWO SIGMA INVESTMENTS, LP
$7.3M2,527,829 sh
BANK OF AMERICA CORP /DE/
$6.9M2,401,814 sh
MARSHALL WACE, LLP
$5.9M2,025,526 sh
RA CAPITAL MANAGEMENT, L.P.
$5.4M1,864,176 sh
WASATCH ADVISORS LP
$4.5M1,559,701 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$3.5M1,208,775 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$17.4M	6,012,000
RENAISSANCE TECHNOLOGIES LLC	$8.6M	2,963,559
MILLENNIUM MANAGEMENT LLC	$8.1M	2,794,357
VANGUARD CAPITAL MANAGEMENT LLC	$7.7M	2,653,853
TWO SIGMA INVESTMENTS, LP	$7.3M	2,527,829
BANK OF AMERICA CORP /DE/	$6.9M	2,401,814
MARSHALL WACE, LLP	$5.9M	2,025,526
RA CAPITAL MANAGEMENT, L.P.	$5.4M	1,864,176
WASATCH ADVISORS LP	$4.5M	1,559,701
VANGUARD PORTFOLIO MANAGEMENT LLC	$3.5M	1,208,775

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MGNX on your watchlist

Track score changes the day MACROGENICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MGNX a good stock to buy?

13F Pro's AI-powered analysis of MACROGENICS INC (MGNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MGNX are available on the MGNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MGNX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MGNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MACROGENICS INC's investment landscape.